BUSINESS
Business content
One-stop service
One-stop service
The company boasts extensive experience in both domestic and international pharmaceutical projects. Its international projects span multiple countries across Eurasia, encompassing dozens of initiatives. Our service offerings cover the entire lifecycle of a drug, including preclinical research, IND submissions, clinical trials (Phase I, Phase II, and Phase III for new drugs, as well as bioequivalence studies for generic drugs), NDA registration, post-marketing studies, pharmacoeconomic evaluations, real-world studies, and more—providing you with professional, one-stop services.
Customized design
The team has over ten years of experience in clinical research for new drugs, covering chemical drugs, traditional Chinese medicines, and biologics. Its key areas of expertise include hematologic malignancies, cell therapies, and the combination of pharmaceuticals with medical devices. Based on the unique characteristics of each drug, and drawing upon the medical team’s specialized knowledge, references to similar cases both domestically and internationally, the latest international technologies, and advice from clinical experts in relevant fields, we develop scientifically sound and highly efficient protocols that comply with laws and regulations, meet patient needs, ensure subject safety, guarantee clinical feasibility, and ensure seamless integration across all stages—thus laying a solid foundation for the smooth execution of the project.
High-efficiency implementation
The implementation of clinical projects relies on the support of more than ten strategic partnership centers, over 300 collaborating clinical centers, and over 1,200 physicians holding positions of associate chief physician or higher. Additionally, we benefit from a team of clinical expert advisors that includes two academicians and 16 renowned professors. Effective communication with authorities such as the NMPA, the National Development and Reform Commission, and the National Health Commission enables our company to maintain keen insights and stay abreast of the latest trends in the domestic pharmaceutical industry at all times. Our professional clinical project team, comprising over 100 members with extensive management experience, carefully assesses key operational points and potential challenges of each project. Dedicated clinical monitors provide comprehensive oversight throughout the entire project lifecycle and prepare detailed progress reports. We also enjoy long-term, collaborative relationships with clinical centers and researchers who are highly professional, experienced in research, and adept at utilizing digital information systems—including electronic case report forms and electronic data management—to achieve centralized monitoring, enhance subject compliance, ensure project safety, and guarantee efficient, cost-effective, and timely completion of projects.
Risk sharing
Through multi-dimensional assessments—including drug-likeness evaluation of new drugs, feasibility analysis of clinical operations, and trend analysis of safety and efficacy—Eurasia Huizhi can participate in the entire process of innovative drug clinical trials in a variety of flexible formats, thereby sharing risks and becoming a long-term partner for pharmaceutical companies on their journey of new drug development.
Business content
Recommended News
MA Achievement Release | Agomelatine Tablets Have Obtained Registration Approval!
Congratulations to Chongqing Huasen Pharmaceutical Co., Ltd. on obtaining the registration certificate for the agomelatine tablet project.
Starting November 1, 2024, applicants for marketing authorization of innovative drugs—as well as products that have been confirmed through communication and consultation to be eligible for the priority review and approval procedure and the conditional approval procedure—will receive early-stage acceptance services.
Follow us
Address: Room 3008, Building I, Yingkun Century, No. 6 Courtyard, East Road of the Automobile Museum, Fengtai District, Beijing
Phone: +86 10 86229816 Fax: 010-83739030
Email: bd-oyhz@healtech.com.cn (Business Cooperation)
ouyahuizhi-hr@healtech.com.cn (Resume Submission)
Follow the official account
WeChat Official Account
Friendship Links:Beijing Aotekang Pharmaceutical Technology Development Co., Ltd. Suzhou Suhao Biomaterials Technology Co., Ltd. Beijing Dikang Pharmaceutical Investment Management Co., Ltd. Center for Drug Evaluation, National Medical Products Administration National Medical Products Administration
Copyright © Eurasia Huizhi (Beijing) Medical Research Co., Ltd.